|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Less common neoplasms of the pancreas显示文摘最近,有除管的腺癌以外的胰的瘤的增加的识别。尽管因为在那里的胰腺的腺癌是展出多样的生物行为和恶意的变化的度的许多不同损害,不也学习了或描绘。这些损害包括:内分泌的瘤,囊性瘤,稳固的假乳头瘤,腺泡房间癌,有鳞的房间癌,胰的主要淋巴瘤,和到胰的变形损害。当诊断成像的数字和敏感学习增加,这些不太普通的瘤更经常正在被诊断。这篇评论文章讨论这些更少的临床的功课,诊断,和治疗普通,却相当相关,胰的瘤。 | Abby L Mulkeen Peter S Yoo Charles Cha | 2006 | World Journal of Gastroenterology2006，12，20： | 24 |
| 2 | Utility of serological markers in inflammatory bowel diseases: Gadget or magic?显示文摘为煽动性的肠疾病(IBD ) 的血清学标记的面板很快正在膨胀。尽管 anti-Saccharomyces 啤酒抗体(ASCA ) 和不正常的仙子细胞质的抗体(P-ANCA ) 仍然是的原子反 neutrophil 广泛地调查的大多数,试验性的数据的增加的数量在对各种各样的微生物引起的抗原指导的最新发现的抗体上是可得到的。对在当前的 IBD 诊断算法的各种各样的抗体的评价的角色由于他们的有限敏感经常是可疑的。相反,有疾病行为和显型的血清学标记的协会正在变得逐渐地生长得很好。越来越多的观察证实有 Crohn 在高乳头 ers 表示多重血清学标记的疾病的病人是更可能的有复杂的小肠疾病(例如苛评或穿孔) 并且没有,或与抗体的低乳头 ers,比那些在为外科的更高的风险。基于血清学反应创造同质的疾病亚群可以帮助开发更多的标准化治疗学的途径并且可以在 IBD 的 pathomechanism 的更好的理解帮助。进一步未来的临床的研究被需要在 IBD 建立 serologic 的临床的角色。 | Maria Papp Gary L Norman Istvan Altorjay Peter Laszlo Lakatos | 2007 | World Journal of Gastroenterology2007，13，14： | 24 |
| 3 | Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease显示文摘AIM To performed a systematic review and meta-analysis to determine any possible differences in terms of effectiveness, safety and tolerability between existing colon-cleansing products in patients with inflammatory bowel disease.METHODS Systematic searches were performed( January 1980-September 2016) using MEDLINE, EMBASE, Scopus, CENTRAL and ISI Web of knowledge for randomized trials assessing preparations with or without adjuvants, given in split and non-split dosing, and in high(> 3 L) or low-volume(2 L or less) regimens. Bowel cleansing quality was the primary outcome. Secondary outcomes included patient willingness-torepeat the procedure and side effects/complications.RESULTS Out of 439 citations, 4 trials fulfilled our inclusion criteria(n = 449 patients). One trial assessed the impact of adding simethicone to polyethylene glycol(PEG) 4 L with no effect on bowel cleansing quality, but a better tolerance. Another trial compared senna to castor oil, again without any differences in term of bowel cleansing. Two trials compared the efficacy of PEG high-volume vs PEG low-volume associated to an adjuvant in split-dose regimens: PEG low-dose efficacy was not different to PEG high-dose; OR = 0.84(0.37-1.92). A higher proportion of patients were willing to repeat low-volume preparations vs high-volume; OR = 5.11(1.31-20.0). CONCLUSION In inflammatory bowel disease population, PEG lowvolume regimen seems not inferior to PEG high-volume to clean the colon, and yields improved willingness-torepeat. Further additional research is urgently required to compare contemporary products in this population. | Sophie Restellini Omar Kherad Talat Bessissow Charles Ménard Myriam Martel Maryam Taheri Tanjani Peter L Lakatos Alan N Barkun | 2017 | World Journal of Gastroenterology2017，23，32： | 16 |
| 4 | miR-182参与调节胶质母细胞瘤的凋亡、生长和分化(英文)显示文摘Glioblastoma multiforme(GBM)is a lethal,therapy-resistant brain cancer consisting of numerous tumor cell subpopulations,including stem-like glioma-initiating cells(GICs),which contribute to tumor recurrence following initial response to therapy.Here,we identified miR-182 as a regulator of apoptosis,growth,and differentiation programs whose expression level is correlated with GBM patient survival.Repression of Bcl2-like12(Bcl2L12),c-Met,and hypoxia-inducible factor 2α(HIF2A)is of central importance to miR-182 anti-tumor activity,as it results in enhanced therapy susceptibility,decreased GIC sphere size,expansion,and stemness in vitro.To evaluate the tumor-suppressive function of miR-182 in vivo,we synthesized miR-182-based spherical nucleic acids(182-SNAs);i.e.,gold nanoparticles covalently functionalized with mature miR-182 duplexes.Intravenously administered 182-SNAs penetrated the bloodbrain/blood-tumor barriers(BBB/BTB)in orthotopic GBM xenografts and selectively disseminated throughout extravascular glioma parenchyma,causing reduced tumor burden and increased animal survival.Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust delivery of 182-SNAs represents a novel strategy for therapeutic intervention in GBM. | Kouri FM Hurley LA Daniel WL Day ES Hua Y Hao L Peng CY Merkel TJ Queisser MA Ritner C Zhang H James CD Sznajder JI Chin L Giljohann DA Kessler JA Peter ME Mirkin CA Stegh AH | 2015 | 中华神经外科疾病研究杂志2015，14，2： | 14 |
| 5 | Abdominal applications of diffusion-weighted magnetic resonance imaging: Where do we stand?显示文摘Diffusion-weighted imaging (DWI) is one of the magnetic resonance imaging (MRI) sequences providing qualitative as well as quantitative information at a cellular level. It has been widely used for various applications in the central nervous system. Over the past decade, various extracranial applications of DWI have been increasingly explored, as it may detect changes even before signal alterations or morphological abnormalities become apparent on other pulse sequences. Initial results from abdominal MRI applications are promising, particularly in oncological settings and for the detection of abscesses. The purpose of this article is to describe the clinically relevant basic concepts of DWI, techniques to perform abdominal DWI, its analysis and applications in abdominal visceral MR imaging, in addition to a brief overview of whole body DWI MRI. | Ajaykumar C Morani Khaled M Elsayes Peter S Liu William J Weadock Janio Szklaruk Jonathan Russell Dillman Asra Khan Thomas L Chenevert Hero K Hussain | 2013 | World Journal of Radiology2013，5，3： | 12 |
| 6 | 欧洲卒中组织(ESO)关于无活动能力的急性缺血性卒中患者静脉血栓栓塞的预防指南显示文摘背景静脉血栓栓塞(venous thromboembolism, VTE)包括深静脉血栓形成(deep vein thrombosis, DVT)和肺栓塞,是无活动能力的急性缺血性卒中患者的常见并发症。本文阐述了欧洲卒中组织(European Stroke Organisation, ESO)关于无活动能力的急性缺血性卒中患者VTE预防的指南。有关出血性卒中的指南已发表。方法一个多学科小组确定了相关问题并使用推荐意见分级评估、制定和评价系统根据随机对照试验证据制定推荐意见。本文经过ESO内部及外部评审,并得到ESO指南委员会和ESO执行委员会批准。结果我们发现的主要是中等质量证据,包括评估梯度压力弹力袜(graduated compression stocking, GCS)、间歇充气加压装置(intermittent pneumatic compression, IPC)以及使用普通肝素(unfractionated heparin, UFH)、低分子量肝素(low molecular weight heparin, LMWH)和类肝素进行预防性抗凝治疗的随机对照试验和系统评价,但未发现评估神经肌肉电刺激(neuromuscular electrical stimulation, NES)的随机试验。我们推荐临床医生对无活动能力的患者使用IPC,但不应使用GCS。在无活动能力的缺血性卒中患者中,如果降低VTE风险的益处足以抵消其使用导致的颅内外出血风险增高,则应考虑使用UFH(5 000 U,2~3次/d)、LMWH或类肝素进行预防性抗凝治疗。如果确定具有预防性抗凝治疗的指征,应考虑使用LMWH或类肝素而非UFH,因为前两者能更明显地降低DVT风险,使用更加便利,人员成本更低,患者舒适度更高(每天仅需注射1次),但这些优势应与LMWH和类肝素的更高颅外出血风险、更高药物成本以及在肾功能不全老年患者中使用的相关风险进行权衡。结论IPC、UFH或LMWH和类肝素可降低无活动能力的急性缺血性卒中患者的VTE风险,但需要进一步研究来评价NES是否有效。其中证据最强的预防手段是IPC。需要更好的方法在卒中发病后最初数周内根据VTE风险和抗凝药的出血风险对患者进行分层。 | Martin Dennis Valeria Caso L Jaap Kappelle Aleksandra Pavlovic Peter Sandercock 刘品一 黄丽丽 徐运 | 2017 | 国际脑血管病杂志2017，25，3： | 11 |
| 7 | Post-transcriptional regulation of vascular endothelial growth factor: Implications for tumor angiogenesis显示文摘脉管的内皮生长因素(VEGF ) 是一个有势力为批评的分泌 mitogen 生理并且肿瘤血管生成。VEGF 的规定发生在几个层次,包括抄写, mRNA 稳定,翻译,和各种各样的 isoforms 的微分细胞的本地化。在我们 VEGF 的 post-transcriptional 规定的理解的最近的进展在 VEGF mRNA 的 5'UTR 包括内部 ribosomal 入口地点的稳定的 mRNA 绑定蛋白质,投,和发现的鉴定。Monoclonal anti-VEGF 抗体最近在人为使用被同意,但是为高全身的剂量受不了需要。RNA 干扰(RNAi ) 技术正在被使用在试管内并且在有有希望的结果的动物模型。这里,我们在 VEGF 的 post-transcriptional 规定上考察文学并且在为治疗学的利益指向这些机制描述最近的进步。 | Peter S Yoo Abby L Mulkeen Charles H Cha | 2006 | World Journal of Gastroenterology2006，12，31： | 11 |
| 8 | 系统综述与网状Meta分析的PRISMA扩展声明显示文摘PRISMA声明旨在提高系统综述和META分析报告的完整性,该声明已经广泛用于指导系统综述和META分析的报告和发表。原始的PRISMA声明是针对两种干预措施比较的传统的系统综述与META分析而制定的,然而,随着多种干预措施比较的系统综述的发展,实施和报告这一类系统综述面临较大挑战。此时,针对网状META分析的PRISMA扩展声明应运而生,旨在提高网状META分析系统综述的报告质量。PRISMA扩展声明是由专家们通过DELPHI调查、面对面讨论和共识大会而最终确立的。PRISMA扩展声明是在原始PRISMA声明的报告清单的基础上经过修改,最终确定了32个条目,每个条目均与网状META分析报告的内容直接相关。本文对网状META分析的PRISMA扩展声明进行了阐述,对报告清单各条目进行了举例说明,并详细说明了在原始PRISMA声明的基础上新增和修改各条目的理由。此外,PRISMA扩展声明强调了在网状META分析的实际操作中需要重点关注的信息。本文的目标读者包括网状META分析的作者与读者,以及期刊杂志的编辑与同行评审。 | 李志霞 杨俊 叶欣 周凌波 杨智荣 孙凤 詹思延 Brian Hutton Georgia Salanti Deborah M.Caldwell Anna Chaimani Christopher H.Schmid Chris Cameron John P.A.Ioannidis Sharon Straus Kristian Thorlund Jeroen P.Jansen Cynthia Mulrow Ferrán Catalá-López Peter C.Gozsche Kay Dickersin Isabelle Boutron Douglas G.Altman David Moher | 2016 | 中国循证心血管医学杂志2016，8，6： | 11 |
| 9 | Endoscopic management of Crohn's strictures显示文摘Symptomatic intestinal strictures develop in more than one third of patients with Crohn's disease(CD) within 10 years of disease onset. Strictures can be inflammatory, fibrotic or mixed and result in a significant decline in quality of life, frequently requiring surgery for palliation of symptoms. Patients under the age of 40 with perianal disease are more likely to suffer from disabling ileocolonic disease thus may have a greater risk for fibrostenotic strictures. Treatment options for fibrostenotic strictures are limited to endoscopic and surgical therapy. Endoscopic balloon dilatation(EBD) appears to be a safe, less invasive and effective alternative modality to replace or defer surgery. Serious complications are rare and occur in less than 3% of procedures. For non-complex strictures without adjacent fistulizaation or perforation that are less than 5 cm in length, EBD should be considered as first-line therapy. The aim of this review is to present the current literature on the endoscopic management of small bowel and colonic strictures in CD, which includes balloon dilatation, adjuvant techniques of intralesional injection of steroids and anti-tumor necrosis factor, and metal stent insertion. Short and long-term outcomes, complications and safety of EBD will be discussed. | Talat Bessissow Jason Reinglas Achuthan Aruljothy Peter L Lakatos Gert Van Assche | 2018 | World Journal of Gastroenterology2018，24，17： | 10 |
| 10 | Immune dysfunction in cirrhosis显示文摘Innate and adaptive immune dysfunction,also referred to as cirrhosis-associated immune dysfunction syndrome,is a major component of cirrhosis,and plays a pivotal role in the pathogenesis of both the acute and chronic worsening of liver function.During the evolution of the disease,acute decompensation events associated with organ failure(s),so-called acute-on chronic liver failure,and chronic decompensation with progression of liver fibrosis and also development of disease specific complications,comprise distinct clinical entities with different immunopathology mechanisms.Enhanced bacterial translocation associated with systemic endotoxemia and increased occurrence of systemic bacterial infections have substantial impacts on both clinical situations.Acute and chronic exposure to bacteria and/or their products,however,can result in variable clinical consequences.The immune status of patients is not constant during the illness;consequently,alterations of the balance between pro-and anti-in-flammatory processes result in very different dynamic courses.In this review we give a detailed overview of acquired immune dysfunction and its consequences for cirrhosis.We demonstrate the substantial influence of inherited innate immune dysfunction on acute and chronic inflammatory processes in cirrhosis caused by the pre-existing acquired immune dysfunction with limited compensatory mechanisms.Moreover,we highlight the current facts and future perspectives of how the assessment of immune dysfunction can assist clinicians in everyday practical decision-making when establishing treatment and care strategies for the patients with end-stage liver disease.Early and efficient recognition of inappropriate performance of the immune system is essential for overcoming complications,delaying progression and reducing mortality. | Nora Sipeki Peter Antal-Szalmas Peter L Lakatos Maria Papp | 2014 | World Journal of Gastroenterology2014，20，10： | 10 |
| 11 | Molecular targets in the treatment of alcoholic hepatitis显示文摘Alcohol related costs to health and society are high. One of the most serious complications of alcohol misuse to the individual is the development of alcoholic hepatitis (AH), a clinical syndrome of jaundice and progressive inflammatory liver injury in patients with a history of recent heavy alcohol use. It has a poor outcome and few existing successful therapies. The use of glucocorticoids in patients with severe AH is still controversial and there remains a group of patients with glucocorticoid-resistant disease. However, as our understanding of the pathogenesis of the condition improves there are opportunities to develop new targeted therapies with specific actions to control liver inflammation without having a detrimental effect on the immune system as a whole. In this article we review the molecular mechanisms of AH concentrating on the activation of the innate and adaptive immune response. We consider existing treatments including glucocorticoids, anti-tumor necrosis factor therapy and pentoxifylline and their limitations. Using our knowledge of the disease pathogenesis we discuss possible novel therapeutic approaches. New targets include pro-inflammatory cytokines such as interleukin (IL)-17, chemokines and their receptors (for example IL-8, CXCL9 and CXCR3) and augmentation of anti-inflam- matory molecules such as IL-10 and IL-22. And there is also future potential to consider combination therapy to selectively modulate the immune response and gain control of disease. | Ashwin D Dhanda Richard WL Lee Peter L Collins C Anne McCune | 2012 | World Journal of Gastroenterology2012，18，39： | 9 |
| 12 | Matched-pair analysis of postoperative morbidity and mortality for pancreaticogastrostomy and pancreaticojejunostomy using mattress sutures in soft pancreatic tissue remnants显示文摘BACKGROUND:After pancreaticoduodenectomy,the incidence of postoperative pancreatic fistula remains high,especially in patients with 'soft' pancreatic tissue remnants.No 'gold standard' surgical technique for pancreaticoenteric anastomosis has been established.This study aimed to compare the postoperative morbidity and mortality of pancreaticogastrostomy and pancreaticojejunostomy for 'soft' pancreatic tissue remnants using modified mattress sutures.METHODS:Seventy-five patients who had undergone pancreaticogastrostomy and 75 who had undergone pancreaticojejunostomy after pancreaticoduodenectomy between 2002 and 2008 were retrospectively compared using matched-pair analysis.A modified mattress suture technique was used for the pancreaticoenteric anastomosis.Patients with an underlying 'hard' pancreatic tissue remnant,as in chronic pancreatitis,were excluded.Both groups were homogeneous for age,gender,and underlying disease.Postoperative morbidity,mortality,and preoperative and operative data were analyzed.RESULTS:There were no significant differences between the groups for the incidence of postoperative pancreatic fistula (10.7% in both).Postoperative morbidity and mortality,median operation time,median length of hospital stay,intraoperative blood loss,and the amount of intraoperatively transfused erythrocyte concentrates also did not significantly differ between the groups.Patient age >65 years (P=0.017),operation time >350minutes (P=0.001),and intraoperative transfusion of erythrocyte concentrates (P=0.038) were identified as risk factors for postoperative morbidity.CONCLUSIONS:Our results showed no significant differences between the groups in the pancreaticogastrostomy and pancreaticojejunostomy anastomosis techniques using mattress sutures for 'soft' pancreatic tissue remnants.In our experience,the mattress sutures are safe and simple to use,and pancreaticogastrostomy in particular is feasible and easy to learn,with good endoscopic accessibility to the anastomosis region.However,the location of the anastomosis and the surgical technique need to be individually evaluated to further reduce the incidence of postoperative pancreatic fistula. | Fritz Klein Marcus Bahra Matthias Glanemann Wladimir Faber Peter Warnick Andreas Andreou Safak Gül Dietmar Jacob | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，1： | 9 |
| 13 | Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer显示文摘Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy.Due to their HLA-independent mode of action,allogeneic Vγ9Vδ2 T cells can be considered for clinical application.To apply allogeneic Vγ9Vδ2 T cells in adoptive immunotherapy,the methodology used to obtain adequate cell numbers with optimal effector function in vitro needs to be optimized,and clinical safety and efficacy also need to be proven.Therefore,we developed a novel formula to improve the expansion of peripheralγδT cells from healthy donors.Then,we used a humanized mouse model to validate the therapeutic efficacy of expandedγδT cells in vivo;furthermore,the expandedγδT cells were adoptively transferred into late-stage liver and lung cancer patients.We found that the expanded cells possessed significantly improved immune effector functions,including proliferation,differentiation,and cancer cell killing,both in vitro and in the humanized mouse model.Furthermore,a phase I clinical trial in 132 late-stage cancer patients with a total of 414 cell infusions unequivocally validated the clinical safety of allogeneic Vγ9Vδ2 T cells.Among these 132 patients,8 liver cancer patients and 10 lung cancer patients who received≥5 cell infusions showed greatly prolonged survival,which preliminarily verified the efficacy of allogeneic Vγ9Vδ2 T-cell therapy.Our clinical studies underscore the safety and efficacy of allogeneic Vγ9Vδ2 T-cell immunotherapy,which will inspire further clinical investigations and eventually benefit cancer patients. | Yan Xu Zheng Xiang Mohammed Alnaggar Léonce Kouakanou Jiawei Li Junyi He Jiashuang Yang Yi Hu Yan Chen Li Lin Jianlei Hao Jingxia Li Jibing Chen Man Li Qingling Wu Christian Peters Qinghua Zhou Jianshuang Li Yingqing Liang Xiaohua Wang Baohui Han Meili Ma Dieter Kabelitz Kecheng Xu Wenwei Tu Yangzhe Wu Zhinan Yin | 2021 | Cellular & Molecular Immunology2021，18，2： | 8 |
| 14 | High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes显示文摘Screening gene function in vivo is a powerful approach to discover novel drug targets. We present high-throughput screening(HTS) data for 3 762 distinct global gene knockout(KO) mouse lines with viable adult homozygous mice generated using either gene-trap or homologous recombination technologies. Bone mass was determined from DEXA scans of male and female mice at 14 weeks of age and by microCT analyses of bones from male mice at 16 weeks of age. Wild-type(WT) cagemates/littermates were examined for each gene KO. Lethality was observed in an additional 850 KO lines. Since primary HTS are susceptible to false positive findings, additional cohorts of mice from KO lines with intriguing HTS bone data were examined. Aging,ovariectomy, histomorphometry and bone strength studies were performed and possible non-skeletal phenotypes were explored. Together, these screens identified multiple genes affecting bone mass: 23 previously reported genes(Calcr, Cebpb, Crtap, Dcstamp, Dkk1, Duoxa2, Enpp1, Fgf23, Kiss1/Kiss1 r, Kl(Klotho),Lrp5, Mstn, Neo1, Npr2, Ostm1, Postn, Sfrp4, Slc30a5, Slc39a13, Sost, Sumf1, Src, Wnt10b), five novel genes extensively characterized(Cldn18, Fam20 c, Lrrk1, Sgpl1, Wnt16), five novel genes with preliminary characterization(Agpat2, Rassf5, Slc10a7, Slc26a7, Slc30a10) and three novel undisclosed genes coding for potential osteoporosis drug targets. | Robert Brommage Jeff Liu Gwenn M Hansen Laura L Kirkpatrick David G Potter Arthur T Ss Brian Zambrowicz David R Powell Peter Vogel | 2014 | Bone Research2014，2，3： | 7 |
| 15 | Determinant-Based Classification of Acute Pancreatitis Severity: An International Multidisciplinary Consultation显示文摘 | E. Patchen Dellinger Christopher E. Forsmark Peter Layer Philippe Lévy Enrique Maraví-Poma Maxim S. Petrov Tooru Shimosegawa Ajith K. Siriwardena Generoso Uomo David C. Whitcomb John A. Windsor | 2012 | Annals of Surgery2012，，6： | 7 |
| 16 | Therapeutic interventions for heart failure with preserved ejection fraction:A summary of current evidence显示文摘Heart failure with preserved ejection fraction(HFPEF)is common and represents a major challenge in cardiovascular medicine.Most of the current treatment of HFPEF is based on morbidity benefits and symptom reduction.Various pharmacological interventions available for heart failure with reduced ejection fraction have not been supported by clinical studies for HFPEF.Addressing the specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of HFPEF.We present a brief overview of the currently recommended therapeutic options with available evidence. | Muhammad Asrar ul Haq Chiew Wong Vivek Mutha Nagesh Anavekar Kwang Lim Peter Barlis David L Hare | 2014 | World Journal of Cardiology2014，6，2： | 7 |
| 17 | Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)显示文摘 | Inzucchi Silvio E Bergenstal Richard M Buse John B Diamant Michaela Ferrannini Ele Nauck Michael Peters Anne L Tsapas Apostolos Wender Richard Matthews David R | 2012 | EN2012，，3： | 6 |
| 18 | Randomized trial in malignant biliary obstruction:Plastic vs partially covered metal stents显示文摘AIM:To compare efficacy and complications of par-tially covered self-expandable metal stent(pcSEMS)to plastic stent(PS)in patients treated for malignant,infrahilar biliary obstruction.METHODS:Multicenter prospective randomized clinical trial with treatment allocation to a pcWallstent(SEMS)or a 10 French PS.Palliative patients aged≥18,for infrahilar malignant biliary obstruction and a Karnofsky performance scale index>60%from 6 participating North American university centers.Primary endpoint was time to stent failure,with secondary outcomes of death,adverse events,Karnofsky performance score and short-form-36 scale administered on a three-monthly basis for up to 2 years.Survival analyses were performed for stent failure and death,with Cox proportional hazards regression models to determine significant predictive characteristics.RESULTS:Eighty-five patients were accrued over 37mo,42 were randomized to the SEMS group and 83patients were available for analyses.Time to stent failure was 385.3±52.5 d in the SEMS and 153.3±19.8 d in the PS group,P=0.006.Time to death did not differ between groups(192.3±23.4 d for SEMS vs211.5±28.0 d for PS,P=0.70).The only significant predictor was treatment allocation,relating to the time to stent failure(P=0.01).Amongst other measured outcomes,only cholangitis differed,being more common in the PS group(4.9%vs 24.5%,P=0.029).The small number of patients in follow-up limits longitudinal assessments of performance and quality of life.From an initially planned 120 patients,only 85 patients were recruited.CONCLUSION:Partially covered SEMS result in a longer duration till stent failure without increased complication rates,yet without accompanying measurable benefits in survival,performance,or quality of life. | Peter L Moses Khalid M AlNaamani Alan N Barkun Stuart R Gordon Roger D Mitty M Stanley Branch Thomas E Kowalski Myriam Martel Viviane Adam | 2013 | World Journal of Gastroenterology2013，19，46： | 6 |
| 19 | 基于局部因素和全身因素对急性胰腺炎严重程度的新分级——概要与解读显示文摘急性胰腺炎严重程度的准确分级对于临床实践和研究十分重要。在临床实践中,准确的分型有助于正确地评估疾病的严重程度,监测疾病的发展,制定治疗策略。而临床研究中,准确的分型对于患者的正确入组、实验结果的有效性都有很大影响。一个多世纪以来,急性胰腺炎的严重程度被简单地分为轻型和重型,而且对于轻型和重型的定义尚未统一。近年来,研究发现重型胰腺炎又有不同的亚组,而不同亚组患者的预后有很大差异,轻型和重型二分法的局限性慢慢显现。 | 李维勤 张璐瑶 黎介寿 E.Patchen Dellinger Christopher E.Forsmark Peter Layer Philippe L'evy Enrique Maravi-Poma Maxim S.Petrov | 2014 | 中华外科杂志2014，52，5： | 6 |
| 20 | Evaluation of the biliary tract in patients with functional biliary symptoms显示文摘这篇论文的目的是在这些病人为胆道的评估描述功能的胆汁的症候群和方法。没有可论证的器官的底层,功能的胆汁的症状能被定义为胆汁的症状。二主要症候群存在:胆囊机能障碍和 Oddi 机能障碍的括约肌。最重要的研究工具是 cholescintigraphy 和 Oddi 测压法的内视镜的括约肌。在胆囊机能障碍 scintigraphic 胆囊喷射部分在下面 35% 能选择将得益于胆囊炎的病人。Oddi 测压法的内视镜的括约肌在 Oddi 机能障碍的括约肌被认为标准答案,但是在 scintigraphic 方法的最近的开发就要改变这。因此, hilum-to-duodenum 运输时间的计算和 cholescintigraphy 上的十二指肠的外观时间在这些病人证明了有用。在结论,周围的方法能诊断功能的胆汁的症候群。然而,仍然有很多个问题,知识进一步被需要。可能,下一个向前走将在感觉测试和阻抗 planimetric 方法的区域。 | Peter Funch-Jensen Asbjφrn Mohr Drewes László Madácsy | 2006 | World Journal of Gastroenterology2006，12，18： | 6 |
您所在的机构暂未开通此部分的功能，请联系管理员